Roche posts 1% rise in fourth-quarter diagnostics sales

Headline results for the fourth quarter:

Diagnostics division sales

CHF 3.4 billion ($3.5 billion)

+1%

Overall revenue

CHF 15.4 billion ($15.9 billion)

+6%

Note: All changes are versus the prior-year period at constant exchange rates unless otherwise stated

What the company said:

"In 2019, Roche achieved excellent operating results," said CEO Severin Schwan, adding that "for 2020 we expect sales growth in the low- to mid-single digit range."

In regard to full-year sales growth, Roche said "centralised and point of care solutions was the main contributor, with growth driven by the immunodiagnostics business. Growth was reported in Asia-Pacific, Latin America and EMEA. In North America, sales were stable."

Other results:

  • Centralised and Point of Care Solutions: CHF 2.1 billion ($2.2 billion), down 2%, with declines in coagulation monitoring more than offsetting immunodiagnostics
  • Molecular Diagnostics: CHF 562 million ($579 million), up 4%, driven by both blood screening and point of care molecular diagnostics
  • Diabetes care: CHF 523 million ($539 million), up 9%
  • Tissue Diagnostics: CHF 305 million ($314 million), down 1%
  • Full-year diagnostics division sales: CHF 12.9 billion ($13.3 billion), up 1% on a reported basis
  • Full-year revenue: CHF 61.5 billion ($63.3 billion), up 8% on a reported basis
  • Full-year profit: CHF 14.1 billion ($14.5 billion), up 30% on a reported basis

Looking ahead:

Roche expects overall revenue to grow in the low- to mid-single digits at constant exchange rates in 2020, with core earnings per share growth forecast to be "broadly in line" with this.

Did you like this article?